DARAPRIM Direct —
A trusted resource when it’s needed most

The DARAPRIM Direct Program was created to help patients obtain quick and affordable access to DARAPRIM.

Through a network of specialty pharmacies and a dedicated support team, DARAPRIM Direct may assist both you and your patients.

To begin the process of prescribing through these specialty pharmacies, please fill out a DARAPRIM Enrollment Form and fax it to the number listed on the form.

DARAPRIM Direct may assist with:

- Dispensing and Delivery
- Insurance Benefits Verification
- Copay Affordability
- Uninsured Patient Support
- Ongoing Support

Contact Us:

To access the DARAPRIM Enrollment Form or to learn more about financial support, visit: www.daraprimdirect.com

To contact the DARAPRIM Direct Program or for questions on accessing DARAPRIM call: 1-877-258-2033, option 2

To report a Suspected Adverse Event for DARAPRIM or for Medical Information inquiries call: 1-877-258-2033, option 1

Please see accompanying Full Prescribing Information or visit www.daraprimdirect.com

Questions? We’re here to help. Call 1-877-258-2033
What You Should Know When Prescribing DARAPRIM

How do I prescribe DARAPRIM?
To prescribe DARAPRIM, fill out the DARAPRIM Enrollment Form and fax it to 1-877-241-1365. The DARAPRIM Enrollment Form can be accessed by visiting www.daraprimdirect.com or through your local DARAPRIM Key Account Manager.

Do I have to fill out all sections of the form?
All indicated sections of the form will need to be filled out for the DARAPRIM Direct Program to process the prescription. Not filling out required information can delay fulfillment of the prescription.

Patients will need to sign the patient authorization on page 2 of the DARAPRIM Enrollment Form to access the financial affordability programs.

How do I e-prescribe DARAPRIM?
Locate the following NPI: 1538590690 in your e-prescribing system and select and save ASPN Pharmacy. If prompted select: “specialty pharmacy” and/or “mail order.” Follow your normal e-prescribing process to submit the order.

How do patients access financial assistance programs?
Patients can access financial assistance programs for DARAPRIM through the DARAPRIM Direct Program. Patients will need to sign the patient authorization on page 2 of the DARAPRIM Enrollment Form to access these programs.

What financial assistance programs are available?¹
- Uninsured patients have access to DARAPRIM for no out-of-pocket cost through the DARAPRIM patient assistance program.

- Through the co-pay assistance program, patients with commercial/private insurance are not obligated to pay more than $10 out of pocket for their DARAPRIM prescription.

- Patients with Medicare Part D insurance coverage have access to an independent charitable foundation, to which the makers of DARAPRIM donate to assist with affordability for disease treatment.

¹Financial assistance programs are subject to terms and conditions and patient eligibility requirements. Restrictions, including where prohibited by law, may apply. Offers are subject to change or discontinuance without notice. Financial assistance programs are not insurance nor are they intended to be a substitute for insurance.

How long does it take for my patients to receive their medication?
Patients should receive their medication in 24-48 hours after the DARAPRIM Direct Program receives the DARAPRIM Enrollment Form, however there can be delays due to benefits verification and your patient’s availability for delivery. If you have questions or concerns, please call 1-877-258-2033.

What happens if the DARAPRIM Direct staff cannot reach my patient?
The DARAPRIM Direct Program will attempt to reach your patient three (3) times. If there is no response, Case Managers will notify your office to confirm the patient’s contact information is correct and to enlist your help to reach the patient if need be.

Are DARAPRIM refills shipped automatically?
If refills are prescribed, the DARAPRIM Direct Case Managers will call the patient to confirm need and delivery address prior to shipping a refill.

Questions? We’re here to help. Call 1-877-258-2033
transmission control and suppression of susceptible strains of plasmodia. 

Chemoprophylaxis of Malaria: DARAPRIM is indicated for the chemoprophylaxis of malaria due to susceptible strains of plasmodia. However, resistance to pyrimethamine is prevalent worldwide. It is not suitable as a prophylactic agent for travelers to most areas.

CONTRAINDICATIONS 
Use of DARAPRIM is contraindicated in patients with known hypersensitivity to pyrimethamine or to any component of the formulation. Use of the drug is also contraindicated in patients with documented megaloblastic anemia due to folate deficiency.

WARNINGS 
The dosage of pyrimethamine required for the treatment of toxoplasmosis is 10 to 20 times the recommended antimalaria dosage and approaches the toxic level. If signs of folate deficiency develop (see ADVERSE REACTIONS), reduce the dosage or discontinue the drug according to the response of the patient. Folinic acid (leucovorin) should be administered in a dosage of 5 to 15 mg daily (orally, IV, or IM) until normal hematopoiesis is restored.

Data in 2 humans indicate that pyrimethamine may be carcinogenic: a 51-year-old female who developed chronic granulocytic leukemia after taking pyrimethamine for 2 years for toxoplasmosis and a 56-year-old patient who developed reticulum cell sarcoma after 14 months of pyrimethamine for toxoplasmosis. Pyrimethamine has been reported to produce a significant increase in the number of lung tumors in mice when given intraperitoneally at doses of 25 mg/kg. 

DARAPRIM should be kept out of the reach of infants and children as they are extremely susceptible to adverse effects from an overdose. Deaths in pediatric patients have been reported after accidental ingestion.

PRECAUTIONS 
General: The recommended dosage for chemoprophylaxis of malaria should not be exceeded. A small “starting” dose for toxoplasmosis is recommended in patients with convulsive disorders to avoid the potential nervous system toxicity of pyrimethamine. DARAPRIM should be used with caution in patients with impaired renal or hepatic function or in patients with possible folate deficiency, such as individuals with malabsorption syndrome, alcoholism, or pregnancy, and those receiving therapy, such as phenytoin, affecting folate levels (see Pregnancy subsection).

Information for Patients: Patients should be warned that at the first appearance of a skin rash they should stop use of DARAPRIM and seek medical attention immediately. Patients should also be warned that the appearance of sore throat, pallor, purpura, or glossitis may be early indications of serious disorders which require treatment with DARAPRIM to be stopped and medical treatment to be sought. Women of childbearing potential who are taking DARAPRIM should be warned against becoming pregnant. Patients should be warned to keep DARAPRIM out of the reach of children. Patients should be advised not to exceed recommended doses. Patients should be warned that if anorexia and vomiting occur, they may be minimized by taking the drug with meals. Concurrent administration of folinic acid is strongly recommended when used for the treatment of toxoplasmosis in all patients.

Laboratory Tests: In patients receiving high dosage, as for the treatment of toxoplasmosis, semiweekly blood counts, including platelet counts, should be performed.

Drug Interactions: Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics. However, the concomitant use of other antifolic drugs or agents associated with myelosuppression including sulfonamides or trimethoprim-sulfamethoxazole combinations, proguanil, zidovudine, or cytostatic agents (e.g., methotrexate), while the patient is receiving pyrimethamine, may increase the risk of bone marrow suppression. If signs of folate deficiency develop, pyrimethamine should be discontinued. Folinic acid (leucovorin) should be administered until normal hematopoiesis is restored (see WARNINGS). Mild hepatotoxicity has been reported in some patients when lorazepam and pyrimethamine were administered concomitantly.

Carcinogenesis, Mutagenesis, Impairment of Fertility: See WARNINGS section for information on carcinogenesis.

Mutagenesis: Pyrimethamine has been shown to be nonmutagenic in the following in vitro assays: the Ames point mutation assay, the Rec assay, and the E. coli WP2 assay. It was positive in the L5178Y/TK +/- mouse lymphoma assay in the absence of exogenous metabolic activation. Human blood lymphocytes cultured in vitro had structural chromosome aberrations induced by pyrimethamine. In vivo, chromosomese analyzed from the bone marrow of rats dosed with pyrimethamine showed an increased number of structural and numerical aberrations.

Pregnancy: Teratogenic Effects: Pregnancy Category C. Pyrimethamine has been shown to be teratogenic in rats when given in oral doses 7 times the human dose for chemoprophylaxis of malaria or 2.5 times the human dose for treatment of toxoplasmosis. At these doses in rats, there was a significant increase in abnormalities such as cleft palate, brachygnathia, oligodactyly, and microphthalmia. Pyrimethamine has also been shown to produce terata such as meningocoele in hamsters and cleft palate in miniature pigs when given in oral doses 170
and 5 times the human dose, respectively, for chemoprophylaxis of malaria or for treatment of toxoplasmosis.

There are no adequate and well-controlled studies in pregnant women. DARAPRIM should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Concurrent administration of folinic acid is strongly recommended when used for the treatment of toxoplasmosis during pregnancy.

**Nursing Mothers:** Pyrimethamine is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from pyrimethamine and from concurrent use of a sulfonamide with DARAPRIM for treatment of some patients with toxoplasmosis, a decision should be made whether to discontinue the drug, taking into account the importance of the drug to the mother (see WARNINGS and PRECAUTIONS: Pregnancy).

**Pediatric Use:** See DOSAGE AND ADMINISTRATION section.

**Geriatric Use:** Clinical studies of DARAPRIM did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosage range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

**ADVERSE REACTIONS**

Hypersensitivity reactions, occasionally severe (such as Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, and anaphylaxis), and hyperphenylalaninemia, can occur particularly when pyrimethamine is administered concomitantly with a sulfonamide. Consult the complete prescribing information for the relevant sulfonamide for sulfonamide-associated adverse events. With doses of pyrimethamine used for the treatment of toxoplasmosis, anorexia and vomiting may occur. Vomiting may be minimized by giving the medication with meals; it usually disappears promptly upon reduction of dosage. Doses used in toxoplasmosis may produce megaloblastic anemia, leukopenia, thrombocytopenia, pancytopenia, neutropenia, atrophic glossitis, hematuria, and disorders of cardiac rhythm. Hematologic effects, however, may also occur at low doses in certain individuals (see PRECAUTIONS; General). Pulmonary eosinophilia has been reported rarely.

**OVERDOSAGE**

Following the ingestion of 300 mg or more of pyrimethamine, gastrointestinal and/or central nervous system signs may be present, including convulsions. The initial symptoms are usually gastrointestinal and may include abdominal pain, nausea, severe and repeated vomiting, possibly including hematemesis. Central nervous system toxicity may be manifest by initial excitability, generalized and prolonged convulsions which may be followed by respiratory depression, circulatory collapse, and death within a few hours. Neurological symptoms appear rapidly (30 minutes to 2 hours after drug ingestion), suggesting that in gross overdose pyrimethamine has a direct toxic effect on the central nervous system.

The fatal dose is variable, with the smallest reported fatal single dose being 375 mg. There are, however, reports of pediatric patients who have recovered after taking 375 to 625 mg. There is no specific antidote to acute pyrimethamine poisoning. In the event of overdose, symptomatic and supportive measures should be employed. Gastric lavage is recommended and is effective if carried out very soon after drug ingestion. Parenteral diazepam may be used to control convulsions. Folinic acid should be administered within 2 hours of drug ingestion to be most effective in counteracting the effects on the hematopoietic system (see WARNINGS). Due to the long half-life of pyrimethamine, daily monitoring of peripheral blood counts is recommended for up to several weeks after the overdose until normal hematologic values are restored.

**DOSAGE AND ADMINISTRATION**

**For Treatment of Toxoplasmosis:** The dosage of DARAPRIM for the treatment of toxoplasmosis must be carefully adjusted so as to provide maximum therapeutic effect and a minimum of side effects. At the dosage required, there is a marked variation in the tolerance to the drug. Young patients may tolerate higher doses than older individuals. Concurrent administration of folic acid is strongly recommended in all patients. The adult starting dose is 50 to 75 mg of the drug daily, together with 1 to 4 g daily of a sulfonamide of the sulfapyrimidine type, e.g., sulfadoxine. This dosage is ordinarily continued for 1 to 3 weeks, depending on the response of the patient and tolerance to therapy. The dosage may then be reduced to about one half that previously given for each drug and continued for an additional 4 to 5 weeks.

The pediatric dosage of DARAPRIM is 1 mg/kg/day divided into 2 equal daily doses; after 2 to 4 days this dose may be reduced to one half and continued for approximately 1 month. The usual pediatric sulfonamide dosage is used in conjunction with DARAPRIM.

**For Treatment of Acute Malaria:** DARAPRIM is NOT recommended alone in the treatment of acute malaria. Fast-acting schizonticides, such as chloroquine or quinine, are indicated for treatment of acute malaria. However, DARAPRIM at a dosage of 25 mg daily for 2 days with a sulfonamide will initiate transmission control and suppression of non-falciparum malaria. DARAPRIM is only recommended for patients infected in areas where susceptible plasmodia exist.

Should circumstances arise wherein DARAPRIM must be used alone in semi-immune persons, the adult dosage for acute malaria is 50 mg for 2 days; children 4 through 10 years old may be given 25 mg daily for 2 days. In any event, clinical cure should be followed by the once-weekly regimen described below for chemoprophylaxis. Regimens which include suppression should be extended through any characteristic periods of early recrudescence and late relapse, i.e., for at least 10 weeks in each case.

**For Chemoprophylaxis of Malaria:**

Adults and pediatric patients over 10 years – 25 mg (1 tablet) once weekly

Children 4 through 10 years – 12.5 mg (½ tablet) once weekly

Infants and children under 4 years – 6.25 mg (¼ tablet) once weekly.

**HOW SUPPLIED:**

White, scored tablets containing 25 mg pyrimethamine, imprinted with “DARAPRIM” and “A3A” in bottles of 100 (NDC 69413-330-10) and bottles of 30 (NDC 69413-330-30).

Store at 15° to 25°C (59° to 77°F) in a dry place and protect from light.

**REFERENCES**


Distributed by: Turing Pharmaceuticals LLC
New York, New York 10036
004967-PI-003
017602 Rev. 10/2016